Alzheimer's Disease Diagnostics Market Size & Growth Forecast 2026–2035, By Segments (End-use, Diagnostics Technique, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Alzheimer's Disease Diagnostics Market size was valued at USD 9.14 Billion in 2025 and is anticipated to grow at a 11.4% CAGR from 2026 to 2035, surpassing USD 26.9 Billion by 2035. The industry revenue for 2026 is estimated at USD 10.07 billion.
Get more details on this report
Request Free Sample ReportAlzheimer's Disease Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to advanced neurology networks, widespread biomarker-based testing, integrated imaging and diagnostics, and high uptake of early cognitive disorder screening.
- Asia Pacific’s 12.77% CAGR is driven by rising awareness of cognitive disorders, expanding neurological diagnostic infrastructure, and improved access to hospital-based evaluation services.
Segment Momentum
- Imaging Techniques held a 43.25% share in 2025 due to their established role in evaluating structural and functional brain changes and supporting routine diagnostic assessments.
- Biomarkers are gaining momentum because they support earlier and more targeted detection approaches, aligning with growing demand for precise characterization of Alzheimer's disease.
Market Expansion Drivers
- Rising aging population accelerating demand for early Alzheimer’s diagnostic screening solutions.
- Expanding biomarker-based blood testing improving non-invasive Alzheimer’s diagnosis accessibility.
- Increasing integration of AI-enabled neuroimaging platforms enhancing diagnostic precision and workflow efficiency.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top players in the alzheimer's disease diagnostics market include F. Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (United States), Abbott Laboratories (United States), Siemens Healthineers AG (Germany), Fujirebio Holdings, Inc. (Japan), Quanterix Corporation (United States), Sysmex Corporation (Japan), C2N Diagnostics, LLC (United States), Labcorp Holdings Inc. (United States), Lantheus Holdings, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As the share of older adults increases, healthcare systems are seeing a larger pool of patients presenting with memory complaints, mild cognitive impairment, and overlapping neurodegenerative symptoms, which is increasing demand for the alzheimer's disease diagnostics market. This trends clinical practice toward earlier screening rather than diagnosis only after functional decline becomes pronounced, because physicians, caregivers, and payers are under greater pressure to distinguish Alzheimer’s disease from normal aging and other dementias sooner. The result is stronger utilization of cognitive assessment tools, imaging, cerebrospinal fluid testing, and emerging blood-based assays as providers build earlier diagnostic pathways around a growing high-risk population.
Expanding biomarker-based blood testing improving non-invasive Alzheimer’s diagnosis accessibility
Biomarker-based blood testing is lowering a major access barrier in the alzheimer's disease diagnostics market by offering a less invasive and more scalable alternative to cerebrospinal fluid collection and specialized imaging. In practice, this expands testing beyond tertiary neurology centers by making it easier for general physicians, outpatient clinics, and broader health networks to incorporate Alzheimer’s evaluation into routine diagnostic workflows. Easier sample collection, simpler patient acceptance, and the potential to support triage before more complex confirmatory procedures are increasing market penetration, especially where capacity constraints and patient reluctance have historically limited timely diagnosis.
Increasing integration of AI-enabled neuroimaging platforms enhancing diagnostic precision and workflow efficiency
AI-enabled neuroimaging platforms are strengthening development of the alzheimer's disease diagnostics market by helping radiologists and neurologists interpret brain scans with greater consistency while reducing the time required for image review. Their practical value lies in supporting earlier recognition of subtle structural and functional patterns associated with Alzheimer’s disease, particularly in cases where manual interpretation can be variable or delayed by specialist shortages. As providers seek tools that improve diagnostic confidence and fit into existing imaging infrastructure, AI integration is influencing market adoption by making advanced neuroimaging more operationally efficient and clinically actionable.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising aging population accelerating demand for early Alzheimer’s diagnostic screening solutions | 2.00% | Moderate | North America, Europe | High | Near Term |
| Expanding biomarker-based blood testing improving non-invasive Alzheimer’s diagnosis accessibility | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Increasing integration of AI-enabled neuroimaging platforms enhancing diagnostic precision and workflow efficiency | 1.40% | Moderate | North America, Asia Pacific, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the largest regional market share in 2025 for the alzheimer's disease diagnostics market, supported by broad access to advanced diagnostic pathways, established neurology care networks, and stronger use of biomarker-based testing in routine clinical decision-making. The region’s leadership is strengthened by the availability of specialized memory clinics, higher testing uptake among aging populations, and a healthcare environment where imaging, laboratory diagnostics, and specialist referrals are more tightly integrated, enabling earlier and more frequent identification of suspected Alzheimer’s cases.
Asia Pacific is projected to expand at a 12.77% CAGR over the forecast period, with growth in the alzheimer's disease diagnostics market accelerating as healthcare systems widen access to neurological assessment and improve diagnostic capacity across large patient populations. Rising awareness of cognitive disorders, expanding use of hospital-based and specialty diagnostic services, and ongoing improvements in healthcare infrastructure are increasing the number of patients entering formal evaluation pathways, which is translating into stronger demand for diagnostic tools across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Diagnostic IntegrationGermany is strengthening the adoption of standardized diagnostic pathways that combine imaging, laboratory testing, and cognitive assessment for Alzheimer's disease. The country places emphasis on integrating innovative diagnostic technologies into established neurological care networks.
France 🇫🇷
Clinical Screening EnhancementFrance is reinforcing structured cognitive screening and advanced diagnostic testing within neurology services to improve Alzheimer's disease evaluation. National research activity also supports the assessment of novel biomarkers for routine clinical practice.
Italy 🇮🇹
Hospital Diagnostic ModernizationItaly is expanding access to specialized Alzheimer's disease diagnostics through hospital-based neurology centers and improved laboratory capabilities. Greater coordination between clinicians and diagnostic providers supports more consistent patient assessment pathways.
Japan 🇯🇵
Aging Care DiagnosticsJapan is prioritizing diagnostic solutions that support timely identification of Alzheimer's disease within its aging population. Healthcare providers are increasing attention on accessible biomarker testing and efficient clinical workflows to improve patient management.
South Korea 🇰🇷
Digital Neurology ExpansionSouth Korea is advancing Alzheimer's disease diagnostics through the integration of digital health technologies, artificial intelligence, and modern laboratory capabilities. Investment in clinical innovation supports broader adoption of earlier diagnostic approaches across healthcare settings.
United States 🇺🇸
Biomarker Adoption FocusThe U.S. is expanding the use of blood-based biomarkers, advanced imaging, and digital diagnostic tools to improve earlier Alzheimer's disease detection. Collaboration between diagnostic developers, healthcare providers, and research institutions continues to support broader clinical integration.
Segment Leadership and Growth Trends
Alzheimer's Disease Diagnostics Market Share (%), End-use, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportAcademic and Research Institutes held the dominant position in the alzheimer's disease diagnostics market in 2025, accounting for a 51.22% share. Their leadership is maintained through their central role in early-stage diagnostic research, validation studies, and the development of testing approaches used to improve disease detection. These institutions typically operate at the front end of scientific investigation, where demand for advanced diagnostic tools remains concentrated, helping Academic and Research Institutes maintain a strong share of end-use activity in the market.
Hospitals are emerging as the fastest-growing end-use segment in the alzheimer's disease diagnostics market as diagnostic evaluation moves closer to routine clinical care. Growth is being underpinned by the practical need to assess cognitive decline within structured care settings where imaging, laboratory testing, and specialist consultation can be coordinated more efficiently than in non-clinical environments. Compared with research-focused users, hospitals are gaining momentum because they are more directly tied to patient diagnosis pathways and real-world treatment decisions.
Diagnostics Technique Segment Analysis: Imaging Techniques (Largest Segment) vs Biomarkers (Fastest-Growing Segment)
In 2025, Imaging Techniques represented the largest segment of the alzheimer's disease diagnostics market with a 43.25% share. This leadership reflects their established use in evaluating structural and functional brain changes associated with Alzheimer’s disease, making them a core part of diagnostic workflows. Imaging Techniques continue to hold a strong share because they are widely relied upon in settings where clinicians need visual evidence to support assessment and differentiation of neurological conditions.
Biomarkers are the fastest-growing diagnostics technique segment in the alzheimer's disease diagnostics market, influenced by the rising need for more targeted and earlier detection approaches. Their momentum is underpinned by the shift toward measuring disease-associated biological changes in a way that can complement or, in some cases, streamline traditional diagnostic methods. Relative to Imaging Techniques, Biomarkers are experiencing stronger uptake because they align more closely with evolving diagnostic requirements focused on earlier identification and more precise characterization of Alzheimer’s disease.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Hospitals, Diagnostic Laboratories, Academic and Research Institutes | Academic and Research Institutes | Hospitals |
| Diagnostics Technique | Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests | Imaging Techniques | Biomarkers |
| Type | Triage, Diagnosis, Screening | Diagnosis | Screening |
Competitive Landscape and Market Positioning
1. F. Hoffmann-La Roche Ltd (Switzerland)
2. Quest Diagnostics Incorporated (United States)
3. Abbott Laboratories (United States)
4. Siemens Healthineers AG (Germany)
5. Fujirebio Holdings Inc. (Japan)
6. Quanterix Corporation (United States)
7. Sysmex Corporation (Japan)
8. C2N Diagnostics LLC (United States)
9. Labcorp Holdings Inc. (United States)
10. Lantheus Holdings Inc. (United States)
The alzheimer's disease diagnostics market is witnessing growing attention toward advanced biomarker identification and non-invasive diagnostic technologies that support early disease detection. Healthcare developers are focusing on imaging advancements, AI-assisted diagnostics, and precision screening tools to improve clinical decision-making. Rising demand for proactive neurological healthcare is also driving innovation within the alzheimer's disease diagnostics market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Beckman Coulter | Jan-25 | Beckman Coulter received FDA Breakthrough Device Designation for its p-Tau217/β-Amyloid plasma ratio test. This blood-based diagnostic tool is designed to identify amyloid pathology associated with Alzheimer's disease, providing healthcare providers with a minimally invasive method to screen patients and guide clinical management decisions. |
| N/A | May-25 | The FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, marking the first regulatory approval for an in vitro diagnostic device designed to assist in Alzheimer's diagnosis using blood analysis. The test is indicated for symptomatic adults aged 55 and older to detect amyloid plaques. |
| C2N Diagnostics | Aug-25 | C2N Diagnostics launched the PrecivityAD2 blood test for individuals aged 50 and older. The test, which recently received validation for this younger demographic, identifies amyloid plaques in the brain to support the diagnosis of early-onset Alzheimer's disease and informs subsequent treatment planning. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Alzheimer's Disease Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Alzheimer's Disease Diagnostics Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of alzheimer's disease diagnostics?
What are the growth projections for the alzheimer's disease diagnostics industry?
How is the shift toward earlier Alzheimer's detection influencing diagnostic adoption?
How are blood-based biomarkers and AI-enabled imaging transforming the Alzheimer's disease diagnostics market?
Why do Imaging Techniques hold the largest share of the Alzheimer's disease diagnostics market?
Why are Biomarkers the fastest-growing diagnostic technique segment?
Why does North America lead Alzheimer's disease diagnostics market?
What is driving growth in Asia Pacific Alzheimer's diagnostics market?
Which companies dominate the alzheimer's disease diagnostics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization